
|Videos|March 27, 2015
Lymph Node Dissection in Bladder Cancer
Advertisement
Episodes in this series

For High-Definition, Click
The number of lymph nodes removed from individuals with muscle-invasive bladder cancer is being used as a surrogate measure for the quality of the dissection, says Dean F. Bajorin, MD. There are studies looking at defining a dissection up to the bifurcation of the iliacs versus up to the bifurcation of the aorta, and whether greater or extended lymph node dissection makes a difference.
It is important to standardize the way the procedure is performed to maintain consistency from institution to institution. Ongoing clinical trials are assessing how a dissection should be defined, including the definitions of standard dissection and extended dissection.
Advertisement
Related to this article

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5










